Clinical Trial

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will test whether MB-CART19.1 is a safe and effective treatment for central nervous system lymphoma (CNSL). This study will test different doses of MB-CART19.1 to find the highest dose that causes few or mild side effects in participants.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-08-15; most recent amendment 2026-06-04.
Trial Details
NCT Number NCT07137494
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Miltenyi Biomedicine GmbH
Conditions Primary Central Nervous System (CNS) Lymphoma, Secondary Central Nervous System Lymphoma
Enrollment 12 participants
Start Date 2025-08-14
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-05